SLC5A2 and polycystic ovary syndrome: Because prior research has shown such tremendous benefits for patients with other medical conditions who are started on an SGLT2 inhibitor, there has been an interest in exploring whether this may be a novel treatment option for patients with PCOS [27,28,29,30].